Immuneering Corp

Immuneering Corp. has appointed Andrew Gengos as its new Chief Financial Officer and Treasurer, effective on or before July 16, 2026. Mr. Gengos brings extensive financial and strategic leadership experience from various biopharmaceutical companies, including Terns Pharmaceuticals and Amgen Inc. He will receive an annual base salary of $530,000, a target annual bonus of 40% of his base salary, and an inducement option to purchase 650,000 shares. Mallory Morales will continue as Senior Vice President Finance and Chief Accounting Officer.

Immuneering Corporation announced the appointment of Andrew Gengos as its new Chief Financial Officer, effective July 16, 2026. Mr. Gengos brings over 25 years of leadership experience in biotech, having most recently served as CFO of Terns Pharmaceuticals, which was acquired by Merck & Co., Inc. for $6.7 billion. He will be responsible for Immuneering's financial strategy, capital allocation, investor relations, and business development as the company advances its lead oncology candidate, atebimetinib, in Phase 3 clinical trials.

Immuneering Corporation announced the dosing of the first patient in MAPKeeper 301, a global, randomized, open-label pivotal Phase 3 clinical trial. This trial evaluates atebimetinib plus modified gemcitabine/nab-paclitaxel (mGnP) in first-line metastatic pancreatic cancer patients, a challenging malignancy with an urgent need for new treatment options. Atebimetinib is a novel MEK inhibitor designed to improve survival and tolerability. Topline data, including the primary endpoint of overall survival, is expected in mid-2028.

Immuneering Corporation announced updated positive data from its Phase 2a clinical trial of atebimetinib in combination with mGnP for first-line pancreatic cancer. The trial showed a median overall survival of 17.3 months, significantly exceeding the 8.5 months reported for standard of care. The drug was generally well-tolerated, with no new safety signals. The company also outlined key upcoming milestones, including the initiation of a pivotal Phase 3 trial for atebimetinib in pancreatic cancer in mid-2026 and a new clinical trial in non-small cell lung cancer in H2 2026.

Immuneering Corporation announced updated positive clinical data from its Phase 2a trial evaluating atebimetinib in combination with modified gemcitabine/nab-paclitaxel (mGnP) in first-line metastatic pancreatic cancer. The study demonstrated a median overall survival of 17.3 months in 55 patients, significantly exceeding the 8.5 months observed with standard of care chemotherapy. The treatment also showed a favorable tolerability profile, with limited severe adverse events and 84% of participants maintaining or gaining weight. The company is actively recruiting for its global Phase 3 MAPKeeper 301 trial, with first patient dosing anticipated in mid-2026.

Immuneering Corp. reported a net loss of $13.46 million for the first quarter of 2026, an improvement from the $15.05 million net loss in the same period last year. The net loss per share also improved to $(0.21) from $(0.42). The company ended the quarter with $47.32 million in cash and cash equivalents and $109.37 million in current marketable securities. Research and development expenses decreased, while general and administrative expenses rose. Immuneering estimates its current cash and marketable securities will fund operations for at least 12 months.

Immuneering Corporation reported its first quarter 2026 financial results, ending the period with $198.6 million in cash, cash equivalents, and marketable securities, with an anticipated cash runway into 2029. The company posted a net loss of $13.5 million, or $0.21 per share. Operationally, Immuneering announced that its pivotal Phase 3 MAPKeeper 301 trial for atebimetinib in first-line metastatic pancreatic cancer is now recruiting patients, with new survival data from its Phase 2a trial slated for presentation at the 2026 ASCO Annual Meeting.

Immuneering Corporation reported Q1 2026 financial results and provided significant business updates, primarily focusing on its clinical pipeline. The company announced that its pivotal Phase 3 MAPKeeper 301 trial for atebimetinib in first-line metastatic pancreatic cancer is now recruiting patients, with the first patient dosing expected by mid-2026. Additionally, new survival data from the Phase 2a trial will be presented at the 2026 ASCO Annual Meeting, and a third-line pancreatic cancer patient demonstrated 27 months of progression-free survival with atebimetinib monotherapy. Immuneering ended Q1 2026 with a strong cash position of $198.6 million, providing an anticipated runway into 2029, while reporting a net loss of $13.5 million.

Immuneering Corp (IMRX) announced that updated data from its Phase 2a clinical trial evaluating atebimetinib in combination with modified gemcitabine/nab-paclitaxel (mGnP) in first-line pancreatic cancer patients will be presented as an oral presentation at the 2026 ASCO Annual Meeting. The presentation will highlight new survival data from an expanded cohort of 55 first-line patients. CEO Ben Zeskind noted atebimetinib's design to improve survival by shrinking tumors, preserving body mass, and maximizing tolerability.